Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of pharmacological and toxicological methods

• Publication date

  2004-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.VASCN.2004.06.003PMID 15385083
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Draft ICH guideline S7B: guideline on safety pharmacology studies for assessing the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals].

  2003cited by this paper
• IKr drug response is modulated by KCR1 in transfected cardiac and noncardiac cell lines

  2003cited by this paper
• Inhibitory effect of erythromycin on potassium currents in rat ventricular myocytes in comparison with disopyramide

  2003cited by this paper
• Functional and pharmacological properties of canine ERG potassium channels.

  2003cited by this paper
• Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.

  2003cited by this paper
• Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics.

  2002cited by this paper
• Inhibitory actions of the selective serotonin re‐uptake inhibitor citalopram on HERG and ventricular L‐type calcium currents

  2002cited by this paper
• Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel.

  2002cited by this paper
• Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine

  2002cited by this paper
• Troubleshooting problems with in vitro screening of drugs for QT interval prolongation using HERG K+ channels expressed in mammalian cell lines and Xenopus oocytes.

  2002influential reference
• A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs.

  2002cited by this paper
• A comparison of currents carried by HERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier current. Is MiRP1 the missing link?

  2002cited by this paper
• Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-à-gogo K(+) channel.

  2001cited by this paper
• Comparison of block among cloned cardiac potassium channels by non-antiarrhythmic drugs

  2001cited by this paper
• Effects of calcium channel blockers on cloned cardiac K+ channels IKr and IKs.

  2000cited by this paper
• High affinity blockade of the HERG cardiac K(+) channel by the neuroleptic pimozide.

  2000cited by this paper
• Probing the Interaction Between Inactivation Gating and d-Sotalol Block of HERG

  2000cited by this paper
• Loratadine blockade of K(+) channels in human heart: comparison with terfenadine under physiological conditions.

  2000influential reference
• Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current.

  1999cited by this paper
• Mechanism of block and identification of the verapamil binding domain to HERG potassium channels.

  1999cited by this paper
• Block of potassium currents in guinea pig ventricular myocytes and lengthening of cardiac repolarization in man by the histamine H1 receptor antagonist diphenhydramine.

  1999cited by this paper
• Modulation of HERG potassium channels by extracellular magnesium and quinidine.

  1999cited by this paper
• Arrhythmogenic mechanisms of non‐sedating antihistamines

  1999cited by this paper
• Bepridil differentially inhibits two delayed rectifier K+ currents, IKr and IKs, in guinea‐pig ventricular myocytes

  1999cited by this paper
• Rate-dependence of antiarrhythmic and proarrhythmic properties of class I and class III antiarrhythmic drugs

  1998cited by this paper
• Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature.

  1998cited by this paper
• Diabetes – renal function – what are the special problems?

  1998cited by this paper
• A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG

  1997cited by this paper
• Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride.

  1997cited by this paper
• Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes.

  1995cited by this paper
• Investigation of the Mechanism by which Ketanserin Prolongs the Duration of the Cardiac Action Potential

  1995cited by this paper
• Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents

  1990cited by this paper
• Penetration of macrolides into human polymorphonuclear leucocytes.

  1989cited by this paper
• On the mechanisms of association of the macrolide antibiotic erythromycin with isolated human polymorphonuclear leucocytes.

  1988cited by this paper

• Effect of the Membrane Environment on Pharmacologic Inhibition of hERG K+ Channel Activity.

  2025cites this paper
• Multi-laboratory comparisons of manual patch clamp hERG data generated using standardized protocols and following ICH S7B Q&A 2.1 best practices

  2025cites this paper
• Quantifying Risk of Delayed QT Prolongation of Ipatasertib in Preclinical and Clinical Studies in Cancer Patients

  2025cites this paper
• Large-scale synthetic data enable digital twins of human excitable cells

  2025cites this paper
• Potential of 6'‑hydroxy justicidin B from Justicia procumbens as a therapeutic agent against coronavirus disease 2019.

  2024cites this paper
• A simulation study of the impact of drug-IKr binding mechanisms on biomarkers of proarrhythmic risk reveals a crucial role in reverse use-dependence of action potential duration and a marked influence on the vulnerable window

  2024cites this paper
• Assessment of corrected JT-peak (JTpc) and Tpeak-to-Tend (TpTec) as proarrhythmia biomarkers in non-human primates: Outcome from a HESI consortium.

  2024cites this paper
• Experimentally validated modeling of dynamic drug-hERG channel interactions reproducing the binding mechanisms and its importance in action potential duration

  2024cites this paper
• Whole‐Cell Configuration of the Patch‐Clamp Technique in the hERG Channel Assay

  2024influential citation
• Inhibition of hERG K channels by verapamil at physiological temperature: Implications for the CiPA initiative.

  2024cites this paper
• Importance of modelling hERG binding in predicting drug-induced action potential prolongations for drug safety assessment

  2023cites this paper
• Optimization of Pharmacokinetic and In Vitro Safety Profile of a Series of Pyridine Diamide Indirect AMPK Activators.

  2023cites this paper
• The Potential Mechanisms behind Loperamide-Induced Cardiac Arrhythmias Associated with Human Abuse and Extreme Overdose

  2023cites this paper
• The Strength of hERG Inhibition by Erythromycin at Different Temperatures Might Be Due to Its Interacting Features with the Channels

  2023influential citation
• Importance of Spatial Arrangement of Cardiomyocyte Network for Precise and Stable On-Chip Predictive Cardiotoxicity Measurement

  2023cites this paper
• hERG block potencies for 5 positive control drugs obtained per ICH E14/S7B Q&As best practices: Impact of recording temperature and drug loss.

  2022cites this paper
• The Challenges of Predicting Drug-Induced QTc Prolongation in Humans

  2022cites this paper
• Design of New Potent and Selective Thiophene-Based KV1.3 Inhibitors and Their Potential for Anticancer Activity

  2022cites this paper
• Translating the measurement of hERG kinetics and drug block for CiPA to a high throughput platform.

  2022cites this paper
• There is no F in APC: Using physiological fluoride-free solutions for high throughput automated patch clamp experiments

  2022cites this paper
• Accurate in silico simulation of the rabbit Purkinje fiber electrophysiological assay to facilitate early pharmaceutical cardiosafety assessment: Dream or reality?

  2022cites this paper
• Use of high throughput ion channel profiling and statistical modeling to predict off-target arrythmia risk - One pharma's experience and perspective.

  2022cites this paper
• Structure activity relationships leading to the identification of the indirect activator of AMPK, R419.

  2022cites this paper
• Metabolic and electrolyte abnormalities as risk factors in drug-induced long QT syndrome

  2022cites this paper
• Preclinical safety evaluation of levonadifloxacin, a novel anti‐methicillin‐resistant Staphyloccocus aureus benzoquinolizine fluoroquinolone by intravenous and oral administration

  2022cites this paper
• The designer benzodiazepine, flubromazepam, induces reward-enhancing and cardiotoxic effects in rodents.

  2022cites this paper
• Automatic modeling of dynamic drug-hERG channel interactions using three voltage protocols and machine learning techniques: A simulation study

  2022cites this paper
• Neurotoxic and cardiotoxic effects of N-methyl-1-(naphthalen-2-yl)propan-2-amine (methamnetamine) and 1-phenyl-2-pyrrolidinylpentane (prolintane)

  2022cites this paper
• Physicochemical QSAR analysis of hERG inhibition revisited: towards a quantitative potency prediction

  2022cites this paper
• Real-Time Monitoring of Changes in Cardiac Contractility Using Silicon Cantilever Arrays Integrated with Strain Sensors.

  2021cites this paper
• Reliable identification of cardiac conduction abnormalities in drug discovery using automated patch clamp II: Best practices for Nav1.5 peak current in a high throughput screening environment.

  2021cites this paper
• Molecular determinants of pro-arrhythmia proclivity of d- and l-sotalol via a multi-scale modeling pipeline

  2021cites this paper
• Inhibition of the hERG potassium channel by phenanthrene: a polycyclic aromatic hydrocarbon pollutant

  2021cites this paper
• In silico Exploration of Interactions Between Potential COVID-19 Antiviral Treatments and the Pore of the hERG Potassium Channel—A Drug Antitarget

  2021cites this paper
• 2-((2-(4-Iodo-2,5-dimethoxyphenyl)ethylamino)methyl)phenol (25I-NBOH) and 2-(((2-(4-chloro-2,5-dimethoxyphenyl)ethyl)amino)methyl)phenol (25C-NBOH) induce adverse effects on the cardiovascular system.

  2021cites this paper
• Cardiac hERG K+ Channel as Safety and Pharmacological Target.

  2021cites this paper
• Use of automated patch clamp in cardiac safety assessment: Past, present & future perspectives.

  2021cites this paper
• Integrated Isogenic Human Induced Pluripotent Stem Cell–Based Liver and Heart Microphysiological Systems Predict Unsafe Drug–Drug Interaction

  2021cites this paper
• Stress-assisted gold micro-wrinkles on a polymer cantilever for cardiac tissue engineering.

  2021cites this paper
• Physiological Roles of the Rapidly Activated Delayed Rectifier K+ Current in Adult Mouse Heart Primary Pacemaker Activity

  2021cites this paper
• Use of automated patch clamp in cardiac safety assessment: Past, present and future perspectives.

  2021cites this paper
• Influence of Kv11.1 (hERG1) K+ channel expression on DNA damage induced by the genotoxic agent methyl methanesulfonate

  2021cites this paper
• Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off‐label in the first wave of COVID‐19

  2021cites this paper
• Preclinical Evaluation of the Effects of Trazpiroben (TAK-906), a Novel, Potent Dopamine D2/D3 Receptor Antagonist for the Management of Gastroparesis

  2021cites this paper
• Safety assessment of metarrestin in dogs: A clinical candidate targeting a subnuclear structure unique to metastatic cancer cells.

  2020cites this paper
• KV11.1, NaV1.5, and CaV1.2 Transporter Proteins as Antitarget for Drug Cardiotoxicity

  2020cites this paper
• Time for a Fully Integrated Nonclinical–Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective

  2020cites this paper
• Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block

  2020cites this paper
• Toward in vivo-relevant hERG safety assessment and mitigation strategies based on relationships between non-equilibrium blocker binding, three-dimensional channel-blocker interactions, dynamic occupancy, dynamic exposure, and cellular arrhythmia

  2020cites this paper
• Reliable identification of cardiac liability in drug discovery using automated patch clamp: Benchmarking best practices and calibration standards for improved proarrhythmic assessment.

  2020cites this paper
• When Does the IC50 Accurately Assess the Blocking Potency of a Drug?

  2020cites this paper
• A systematic strategy for estimating hERG block potency and its implications in a new cardiac safety paradigm

  2020cites this paper
• Automated Dynamic Clamp for Simulation of IK1 in Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes in Real Time Using Patchliner Dynamite8

  2020cites this paper
• Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in recombinant cells

  2020cites this paper
• Blinded In Silico Drug Trial Reveals the Minimum Set of Ion Channels for Torsades de Pointes Risk Assessment

  2020cites this paper
• 2-(2,5-Dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamine (25D-NBOMe) and N-(2-methoxybenzyl)-2,5-dimethoxy-4-chlorophenethylamine (25C-NBOMe) induce adverse cardiac effects in vitro and in vivo.

  2019cites this paper
• Quantitative Systems Pharmacology Models for a New International Cardiac Safety Regulatory Paradigm: An Overview of the Comprehensive In Vitro Proarrhythmia Assay In Silico Modeling Approach

  2019cites this paper
• Rapid Characterization of hERG Channel Kinetics II: Temperature Dependence

  2019cites this paper
• Cardiotoxic effects of [3-[2-(diethylamino)ethyl]-1H-indol-4-yl] acetate and 3-[2-[ethyl(methyl)amino]ethyl]-1H-indol-4-ol: Short title: QT prolongation by 4-acetoxy-DET and 4-hydroxy-MET.

  2019cites this paper
• General Principles for the Validation of Proarrhythmia Risk Prediction Models: An Extension of the CiPA In Silico Strategy

  2019cites this paper
• Functional and pharmacological characterization of an S5 domain hERG mutation associated with short QT syndrome

  2019cites this paper
• Characteristics of hERG and hNav1.5 channel blockade by sulcardine sulfate, a novel anti‐arrhythmic compound

  2019cites this paper
• Rapid characterisation of hERG channel kinetics I: using an automated high-throughput system

  2019cites this paper
• Human Heart Cardiomyocytes in Drug Discovery and Research: New Opportunities in Translational Sciences.

  2019cites this paper
• Drug potency on inhibiting late Na+ current is sensitive to gating modifier and current region where drug effects were measured.

  2019cites this paper
• Usefulness of Bnet, a Simple Linear Metric in Discerning Torsades De Pointes Risks in 28 CiPA Drugs

  2019cites this paper
• Protocol-Dependent Differences in IC50 Values Measured in Human Ether-Á-Go-Go–Related Gene Assays Occur in a Predictable Way and Can Be Used to Quantify State Preference of Drug Binding

  2019cites this paper
• Nonclinical safety assessment of PF614: A novel TAAP prodrug of oxycodone for chronic pain indication.

  2019cites this paper
• Pressure-dependent Modulation of Inward-Rectifying K+ Channels: Implications for Cation Homeostasis and K+ Dynamics in Glaucoma.

  2019cites this paper
• Rapid Characterization of hERG Channel Kinetics I: Using an Automated High-Throughput System

  2019cites this paper
• Introduction to biological complexity as a missing link in drug discovery

  2018cites this paper
• Evaluation of Possible Proarrhythmic Potency: Comparison of the Effect of Dofetilide, Cisapride, Sotalol, Terfenadine, and Verapamil on hERG and Native IKr Currents and on Cardiac Action Potential

  2018cites this paper
• Computational modeling of the effect of temperature variations on human pancreatic β-cell activity.

  2018cites this paper
• Investigation of hERG1b Influence on hERG Channel Pharmacology at Physiological Temperature

  2018cites this paper
• In Vitro and In Silico Risk Assessment in Acquired Long QT Syndrome: The Devil Is in the Details

  2017influential citation
• Natural products modulating the hERG channel: heartaches and hope† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c7np00014f

  2017cites this paper
• Characterization of loperamide-mediated block of hERG channels at physiological temperature and its proarrhythmia propensity.

  2017cites this paper
• Evidence for the hERG Liability of Antihistamines, Antipsychotics, and Anti‐Infective Agents: A Systematic Literature Review From the ARITMO Project

  2017cites this paper
• Observations on conducting whole‐cell patch clamping of the hERG cardiac K+ channel in pure human serum

  2017cites this paper
• Safety pharmacology methods and models in an evolving regulatory environment.

  2017cites this paper
• The utility of human iPS cell-derived cardiomyocytes in predicting the clinical risk of drugs that display discordance of cardiotoxicity by species

  2017influential citation
• A new paradigm for drug-induced torsadogenic risk assessment using human iPS cell-derived cardiomyocytes.

  2017cites this paper
• Cardiac voltage-gated ion channels in safety pharmacology: Review of the landscape leading to the CiPA initiative.

  2017cites this paper
• Measuring kinetics and potency of hERG block for CiPA.

  2017cites this paper
• Automated Patch-Clamp Methods for the hERG Cardiac Potassium Channel.

  2017cites this paper
• Proarrhythmic risk assessment using conventional and new in vitro assays

  2017cites this paper
• Overexpression of KCNJ2 in induced pluripotent stem cell-derived cardiomyocytes for the assessment of QT-prolonging drugs.

  2017cites this paper
• Clenbuterol Attenuates hERG Channel by Promoting the Mature Channel Degradation

  2017cites this paper
• Development of in vitro Drug Screening Platforms Using Human Induced Pluripotent Stem Cell-Derived Cardiovascular Cells

  2017cites this paper
• A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm

  2016cites this paper
• Early drug development: assessment of proarrhythmic risk and cardiovascular safety

  2016cites this paper
• Assessment of drug-induced arrhythmic risk using limit cycle and autocorrelation analysis of human iPSC-cardiomyocyte contractility.

  2016cites this paper
• Effects of Temperature on Heteromeric Kv11.1a/1b and Kv11.3 Channels.

  2016cites this paper
• The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress.

  2016cites this paper
• Explorer State dependent dissociation of HERG channel inhibitors

  2016influential citation
• Application of a systems pharmacology model for translational prediction of hERG‐mediated QTc prolongation

  2016cites this paper
• Automated Patch Clamp Meets High-Throughput Screening

  2016cites this paper
• Comprehensive in vitro Proarrhythmia Assay (CiPA): Pending issues for successful validation and implementation.

  2016cites this paper
• Safety pharmacology studies using EFP and impedance.

  2016cites this paper
• PKPD modelling of drug-induced QTc interval prolongation in man : prediction from in vitro hERG binding and functional inhibition assays and conscious dog studies

  2016cites this paper